{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T05:18:08Z","timestamp":1738300688249,"version":"3.35.0"},"reference-count":50,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022083","name":"VLIRUOS","doi-asserted-by":"publisher","award":["TZ2017TEA451A102"],"award-info":[{"award-number":["TZ2017TEA451A102"]}],"id":[{"id":"10.13039\/501100022083","id-type":"DOI","asserted-by":"publisher"}]},{"name":"EDCTP2 programme supported by the European Union","award":["TMA2015SF\u2013998-MaReCa"],"award-info":[{"award-number":["TMA2015SF\u2013998-MaReCa"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Several interventional strategies have been implemented in malaria endemic areas where the burden is high, that include among others, intermittent preventive treatment (IPT), a tactic that blocks transmission and can reduce disease morbidity. However, the implementation IPT strategies raises a genuine concern, intervening the development of naturally acquired immunity to malaria which requires continuous contact with parasite antigens. This study investigated whether dihydroartemisinin-piperaquine (DP) or artesunate-amodiaquine (ASAQ) IPT in schoolchildren (IPTsc) impairs IgG reactivity to six malaria antigens. An IPTsc trial in north-eastern Tanzania administered three doses of DP or ASAQ at four-monthly intervals and the schoolchildren were followed up. This study compared IgG reactivity against GLURP-R2, MSP1, MSP3, and CIDR domains (CIDRa1.1, CIDRa1.4, and CIDRa1.5) of <jats:italic>Plasmodium falciparum<\/jats:italic> erythrocyte membrane protein 1 (PfEMP-1) in intervention and control groups using enzyme linked immunosorbent assay (ELISA) technique. During the study, 369 schoolchildren were available for analysis, 119, 134 and 116 participants in the control, DP and ASAQ groups, respectively. Breadth of malaria antigen recognition increased significantly during and after the intervention phases and did not differ between the study groups (Trend test: DP, z-score = 5.92, <jats:italic>p<\/jats:italic> &lt; 0.001, ASAQ, z-score = 6.64, <jats:italic>p<\/jats:italic> &lt; 0.001 and control, z-score = 5.85, <jats:italic>p<\/jats:italic> &lt; 0.001). There were no differences between the control and ASAQ group in the recognition of any of the tested antigens at all visits. In the DP group, however, during the intervention period IPTsc did not impair antibody against MSP1, MSP3, CIDRa1.1, CIDRa1.4 and CIDRa1.5, but it did impair against GLURP-R2. The current study has shown that effective IPTsc with DP or ASAQ does not interfere with the development of antibodies against malaria antigens of the blood stages, suggesting that the advancement of naturally acquired immunity to malaria is not impeded by IPTsc interventions.<\/jats:p>","DOI":"10.1371\/journal.pone.0316482","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T18:45:07Z","timestamp":1738262707000},"page":"e0316482","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of intermittent preventive treatment in school aged children with dihydroartemisinin piperaquine and artesunate amodiaquine on IgG response against six blood stage Plasmodium falciparum antigens"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1904-7410","authenticated-orcid":true,"given":"Eric","family":"Lyimo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geofrey","family":"Makenga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Turner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lavstsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P. A.","family":"Lusingu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Van geertruyden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel T. R.","family":"Minja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian W.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vito","family":"Baraka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"pone.0316482.ref001","first-page":"978-92-4","volume-title":"World malaria report.","author":"WHO","year":"2023"},{"key":"pone.0316482.ref002","volume-title":"Guidelines for malaria, 14 March 2023.","author":"WHO","year":"2023"},{"key":"pone.0316482.ref003","volume-title":"WHO Policy Recommendation: Seasonal Malaria Chemoprevention (SMC) for Plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa.","author":"WHO","year":"2012"},{"issue":"1","key":"pone.0316482.ref004","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s12936-020-03196-7","article-title":"Rapid shifts in the age-specific burden of malaria following successful control interventions in four regions of Uganda.","volume":"19","author":"SP Kigozi","year":"2020","journal-title":"Malar J"},{"issue":"10","key":"pone.0316482.ref005","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/cid\/ciu150","article-title":"Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial","volume":"58","author":"JI Nankabirwa","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0316482.ref006","doi-asserted-by":"crossref","first-page":"e1499","DOI":"10.1016\/S2214-109X(20)30325-9","article-title":"Preventive malaria treatment among school-aged children in sub-Saharan Africa: a systematic review and meta-analyses","volume":"8","author":"LM Cohee","year":"2020","journal-title":"Lancet Glob Health"},{"key":"pone.0316482.ref007","doi-asserted-by":"crossref","first-page":"e00188","DOI":"10.1016\/j.parepi.2020.e00188","article-title":"Prevalence of malaria parasitaemia in school-aged children and pregnant women in endemic settings of sub-Saharan Africa: A systematic review and meta-analysis.","volume":"11","author":"G Makenga","year":"2020","journal-title":"Parasite Epidemiol Control"},{"key":"pone.0316482.ref008","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1186\/s12936-015-0988-5","article-title":"Efficacy and safety of intermittent preventive treatment for malaria in schoolchildren: a systematic review.","volume":"14","author":"JR Matangila","year":"2015","journal-title":"Malar J."},{"issue":"3","key":"pone.0316482.ref009","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ijantimicag.2016.11.017","article-title":"Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine\/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial.","volume":"49","author":"JR Matangila","year":"2017","journal-title":"Int J Antimicrob Agents."},{"issue":"8","key":"pone.0316482.ref010","doi-asserted-by":"crossref","first-page":"e1277","DOI":"10.1016\/S2214-109X(23)00204-8","article-title":"Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial","volume":"11","author":"G Makenga","year":"2023","journal-title":"Lancet Glob Health"},{"issue":"4","key":"pone.0316482.ref011","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1093\/infdis\/jiq079","article-title":"Follow-up survey of children who received sulfadoxine-pyrimethamine for intermittent preventive antimalarial treatment in infants","volume":"203","author":"R Kobbe","year":"2011","journal-title":"J Infect Dis"},{"issue":"6","key":"pone.0316482.ref012","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0035-9203(95)90419-0","article-title":"Mortality and morbidity from malaria after stopping malaria chemoprophylaxis","volume":"89","author":"BM Greenwood","year":"1995","journal-title":"Trans R Soc Trop Med Hyg"},{"issue":"8","key":"pone.0316482.ref013","doi-asserted-by":"crossref","first-page":"e0237671","DOI":"10.1371\/journal.pone.0237671","article-title":"Antibodies to full-length and the DBL5 domain of VAR2CSA in pregnant women after long-term implementation of intermittent preventive treatment in Etoudi, Cameroon.","volume":"15","author":"JC Djontu","year":"2020","journal-title":"PLoS One."},{"issue":"10","key":"pone.0316482.ref014","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-3156.2007.01902.x","article-title":"Immune responses after single-dose sulphadoxine-pyrimethamine indicate underestimation of protective efficacy of intermittent preventive treatment in infants","volume":"12","author":"N Schreiber","year":"2007","journal-title":"Trop Med Int Health"},{"key":"pone.0316482.ref015","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1475-2875-9-363","article-title":"Immunological consequences of intermittent preventive treatment against malaria in Senegalese preschool children.","volume":"9","author":"D Boulanger","year":"2010","journal-title":"Malar J"},{"issue":"7","key":"pone.0316482.ref016","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.imbio.2010.12.010","article-title":"IgG against Plasmodium falciparum variant surface antigens and growth inhibitory antibodies in Mozambican children receiving intermittent preventive treatment with sulfadoxine-pyrimethamine","volume":"216","author":"D Quelhas","year":"2011","journal-title":"Immunobiology"},{"key":"pone.0316482.ref017","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12936-015-0977-8","article-title":"High-level Plasmodium falciparum sulfadoxine-pyrimethamine resistance with the concomitant occurrence of septuple haplotype in Tanzania.","volume":"14","author":"V Baraka","year":"2015","journal-title":"Malar J"},{"issue":"1","key":"pone.0316482.ref018","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12879-020-05253-7","article-title":"Occurrence of septuple and elevated Pfdhfr-Pfdhps quintuple mutations in a general population threatens the use of sulfadoxine-pyrimethamine for malaria prevention during pregnancy in eastern-coast of Tanzania.","volume":"20","author":"GM Bwire","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"7455","key":"pone.0316482.ref019","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nature12216","article-title":"Severe malaria is associated with parasite binding to endothelial protein C receptor","volume":"498","author":"L Turner","year":"2013","journal-title":"Nature"},{"issue":"4","key":"pone.0316482.ref020","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00841-16","article-title":"The Severity of Plasmodium falciparum Infection Is Associated with Transcript Levels of var Genes Encoding Endothelial Protein C Receptor-Binding P. falciparum Erythrocyte Membrane Protein 1","volume":"85","author":"SI Mkumbaye","year":"2017","journal-title":"Infection and immunity"},{"issue":"12","key":"pone.0316482.ref021","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.137262","article-title":"Longitudinal analysis of naturally acquired PfEMP1 CIDR domain variant antibodies identifies associations with malaria protection.","volume":"5","author":"N Obeng-Adjei","year":"2020","journal-title":"JCI insight."},{"issue":"8","key":"pone.0316482.ref022","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1128\/IAI.00271-15","article-title":"IgG antibodies to endothelial protein C receptor-binding cysteine-rich interdomain region domains of Plasmodium falciparum erythrocyte membrane protein 1 are acquired early in life in individuals exposed to malaria","volume":"83","author":"L Turner","year":"2015","journal-title":"Infection and immunity"},{"issue":"1","key":"pone.0316482.ref023","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1186\/s12936-019-2831-x","article-title":"Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.","volume":"18","author":"R Adamou","year":"2019","journal-title":"Malar J"},{"key":"pone.0316482.ref024","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12936-016-1146-4","article-title":"Antibody levels against GLURP R2, MSP1 block 2 hybrid and AS202.11 and the risk of malaria in children living in hyperendemic (Burkina Faso) and hypo-endemic (Ghana) areas.","volume":"15","author":"B Adu","year":"2016","journal-title":"Malar J"},{"key":"pone.0316482.ref025","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1475-2875-4-48","article-title":"Cytophilic antibodies to Plasmodium falciparum glutamate rich protein are associated with malaria protection in an area of holoendemic transmission.","volume":"4","author":"JP Lusingu","year":"2005","journal-title":"Malar J"},{"issue":"6","key":"pone.0316482.ref026","doi-asserted-by":"crossref","first-page":"2174","DOI":"10.4269\/ajtmh.18-0805","article-title":"Antibody Correlates of Protection from Clinical Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission","volume":"103","author":"KES Hamre","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0316482.ref027","doi-asserted-by":"crossref","first-page":"100546","DOI":"10.1016\/j.conctc.2020.100546","article-title":"Effectiveness and safety of intermittent preventive treatment for malaria using either dihydroartemisinin-piperaquine or artesunate-amodiaquine in reducing malaria related morbidities and improving cognitive ability in school-aged children in Tanzania: A study protocol for a controlled randomised trial.","volume":"17","author":"G Makenga","year":"2020","journal-title":"Contemp Clin Trials Commun"},{"key":"pone.0316482.ref028","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1186\/s12889-016-3287-3","article-title":"The effectiveness of non-pyrethroid insecticide-treated durable wall lining to control malaria in rural Tanzania: study protocol for a two-armed cluster randomized trial.","volume":"16","author":"G Mtove","year":"2016","journal-title":"BMC Public Health"},{"issue":"1","key":"pone.0316482.ref029","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1186\/s12879-022-07820-6","article-title":"Seroprevalence of SARS-CoV-2 antibodies among children and adolescents recruited in a malariometric survey in north-eastern Tanzania July 2021.","volume":"22","author":"E Lyimo","year":"2022","journal-title":"BMC Infect Dis."},{"key":"pone.0316482.ref030","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/1475-2875-7-108","article-title":"A semi-automated multiplex high-throughput assay for measuring IgG antibodies against Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) domains in small volumes of plasma.","volume":"7","author":"GK Cham","year":"2008","journal-title":"Malar J."},{"issue":"1","key":"pone.0316482.ref031","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/1475-2875-7-195","article-title":"Dried blood spots as a source of anti-malarial antibodies for epidemiological studies","volume":"7","author":"PH Corran","year":"2008","journal-title":"Malar J"},{"issue":"3","key":"pone.0316482.ref032","doi-asserted-by":"crossref","DOI":"10.1128\/IAI.00679-19","article-title":"In Vivo Imaging of the Buccal Mucosa Shows Loss of the Endothelial Glycocalyx and Perivascular Hemorrhages in Pediatric Plasmodium falciparum Malaria","volume":"88","author":"E Lyimo","year":"2020","journal-title":"Infection and immunity"},{"issue":"6","key":"pone.0316482.ref033","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jclinepi.2011.11.012","article-title":"Multiple imputation of missing repeated outcome measurements did not add to linear mixed-effects models.","volume":"65","author":"SA Peters","year":"2012","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"pone.0316482.ref034","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s12936-022-04428-8","article-title":"Implementation research of a cluster randomized trial evaluating the implementation and effectiveness of intermittent preventive treatment for malaria using dihydroartemisinin-piperaquine on reducing malaria burden in school-aged children in Tanzania: methodology, challenges, and mitigation.","volume":"22","author":"G Makenga","year":"2023","journal-title":"Malar J"},{"issue":"10","key":"pone.0316482.ref035","doi-asserted-by":"crossref","first-page":"e7590","DOI":"10.1371\/journal.pone.0007590","article-title":"The quantity and quality of African children\u2019s IgG responses to merozoite surface antigens reflect protection against Plasmodium falciparum malaria.","volume":"4","author":"D Courtin","year":"2009","journal-title":"PLoS One"},{"issue":"2","key":"pone.0316482.ref036","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1093\/infdis\/jiz088","article-title":"Breadth of Functional Antibodies Is Associated With Plasmodium falciparum Merozoite Phagocytosis and Protection Against Febrile Malaria","volume":"220","author":"IH Kana","year":"2019","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0316482.ref037","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/AAC.00955-07","article-title":"Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand","volume":"52","author":"J Tarning","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0316482.ref038","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1128\/CVI.00044-08","article-title":"Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique.","volume":"15","author":"D Quelhas","year":"2008","journal-title":"Clinical and vaccine immunology: CVI."},{"issue":"1","key":"pone.0316482.ref039","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12936-017-1935-4","article-title":"Effect of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali.","volume":"16","author":"A Mahamar","year":"2017","journal-title":"Malar J"},{"issue":"1","key":"pone.0316482.ref040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12936-020-03542-9","article-title":"Effect of 4 years of seasonal malaria chemoprevention on the acquisition of antibodies to Plasmodium falciparum antigens in Ouelessebougou, Mali.","volume":"20","author":"A Mahamar","year":"2021","journal-title":"Malar J."},{"key":"pone.0316482.ref041","doi-asserted-by":"crossref","first-page":"107102","DOI":"10.1016\/j.ijid.2024.107102","article-title":"Lack of selection of antimalarial drug resistance markers after intermittent preventive treatment of schoolchildren (IPTsc) against malaria in northeastern Tanzania.","volume":"146","author":"F Von Wowern","year":"2024","journal-title":"Int J Infect Dis"},{"issue":"1","key":"pone.0316482.ref042","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s12936-019-2730-1","article-title":"Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania.","volume":"18","author":"DS Ishengoma","year":"2019","journal-title":"Malar J."},{"key":"pone.0316482.ref043","doi-asserted-by":"crossref","first-page":"594653","DOI":"10.3389\/fimmu.2020.594653","article-title":"Naturally Acquired Humoral Immunity Against Plasmodium falciparum Malaria","volume":"11","author":"SJ Gonzales","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0316482.ref044","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1017\/S0031182017001949","article-title":"Mechanisms of naturally acquired immunity to P. falciparum and approaches to identify merozoite antigen targets","volume":"145","author":"J Healer","year":"2018","journal-title":"Parasitology"},{"issue":"7","key":"pone.0316482.ref045","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1080\/14760584.2018.1488591","article-title":"A vaccine targeted specifically to prevent cerebral malaria\u2014is there hope?","volume":"17","author":"L Hviid","year":"2018","journal-title":"Expert Rev Vaccines."},{"issue":"5","key":"pone.0316482.ref046","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.chom.2019.10.012","article-title":"Protective Immunity against Severe Malaria in Children Is Associated with a Limited Repertoire of Antibodies to Conserved PfEMP1 Variants.","volume":"26","author":"SK Tessema","year":"2019","journal-title":"Cell Host Microbe."},{"issue":"9","key":"pone.0316482.ref047","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1080\/14760584.2017.1355246","article-title":"The GMZ2 malaria vaccine: from concept to efficacy in humans","volume":"16","author":"M Theisen","year":"2017","journal-title":"Expert Rev Vaccines"},{"key":"pone.0316482.ref048","doi-asserted-by":"crossref","first-page":"899223","DOI":"10.3389\/fimmu.2022.899223","article-title":"GMZ2 Vaccine-Induced Antibody Responses, Naturally Acquired Immunity and the Incidence of Malaria in Burkinabe Children.","volume":"13","author":"S Dassah","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"pone.0316482.ref049","doi-asserted-by":"crossref","DOI":"10.1172\/JCI175707","article-title":"A randomized first-in-human phase I trial of differentially adjuvanted Pfs48\/45 malaria vaccines in Burkinabe adults","volume":"134","author":"AB Tiono","year":"2024","journal-title":"J Clin Invest"},{"issue":"1","key":"pone.0316482.ref050","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s13071-017-2338-7","article-title":"Natural antibody responses to Plasmodium falciparum MSP3 and GLURP(R0) antigens are associated with low parasite densities in malaria patients living in the Central Region of Ghana.","volume":"10","author":"LE Amoah","year":"2017","journal-title":"Parasit Vectors"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316482","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T18:45:28Z","timestamp":1738262728000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0316482"}},"subtitle":[],"editor":[{"given":"Enoch","family":"Aninagyei","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1,30]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0316482","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,30]]}}}